Developing an efficient and reliable dry powder inhaler for pulmonary drug delivery - A review for multidisciplinary researchers

Medical Engineering and Physics

Volumn 34, Issue 4, 2012, Pages 409-427

  Islam, Nazrul ^a   Cleary, Matthew J ^b,c  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Device design; Dry powder inhalation; Powder formulation; Pulmonary drug delivery

Indexed keywords

CLINICAL EFFICACY; DEAGGLOMERATION; DEVICE DESIGN; DRUG FORMULATIONS; DRY POWDER INHALER; DRY POWDERS; ENGINEERING DEVELOPMENT; MEDICAL TECHNOLOGIES; PHYSICAL PROCESS; PULMONARY DRUG DELIVERY; RESEARCH AND DEVELOPMENT; THERAPEUTIC BENEFITS;

BIOMEDICAL ENGINEERING; DRUG DELIVERY; DRUG DOSAGE;

DESIGN;

AGENTS ACTING ON THE GENITAL SYSTEM; ANTIBIOTIC AGENT; ATROPINE; BUDESONIDE; CHITOSAN; CIPROFLOXACIN; CYCLODEXTRIN; DRUG CARRIER; FENTANYL; FLUOROURACIL; FORMOTEROL; HEPARIN; INFLUENZA VACCINE; LEVODOPA; LEVONORGESTREL; LIPOSOME; MALARIA VACCINE; MEASLES VACCINE; NANOPARTICLE; NEDOCROMIL; NIFEDIPINE; OPIATE DERIVATIVE; POLYMER; RECOMBINANT HUMAN INSULIN; SALBUTAMOL; SMALL INTERFERING RNA; TERBUTALINE; TIOTROPIUM BROMIDE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

AEROSOL; AIRWAY RESISTANCE; ASTHMA; BIOENGINEERING; CANCER PAIN; CLINICAL EFFECTIVENESS; COMPUTATIONAL FLUID DYNAMICS; DIAGNOSTIC TEST; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG LEGISLATION; DRUG RESEARCH; EQUIPMENT DESIGN; FLOWMETER; FLUIDIZATION; HUMAN; HUMIDITY; INHALATION; MEDICAL LITERATURE; MEDICAL TECHNOLOGY; MORPHOLOGY; PARKINSON DISEASE; PATIENT EDUCATION; PATIENT INFORMATION; PHYSICAL CHEMISTRY; POWDER INHALER; PRIORITY JOURNAL; RESPIRATORY AIRFLOW; REVIEW;

DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; ENGINEERING; HUMANS; LUNG;

EID: 84859735921     PISSN: 13504533     EISSN: 18734030     Source Type: Journal    
DOI: 10.1016/j.medengphy.2011.12.025     Document Type: Review

References (231)

1. Patton J.S. Pulmonary drug delivery comes of age: the outlook for 2005 & beyond. Drug Deliv Technol 2005, 5(44):6-9.
2. PRWEB. Global pulmonary drug delivery technologies market. Accessed 51011; 2010. http://wwwstrategyrcom/Pulmonary_Drug_Delivery_Technologies_Market_Reportasp.
3. DiNunzio J.C., McGinity J.W., Williams R.O. A review of development & design technology for next-generation dry powder inhalers. Drug Deliv Technol 2007, 7:22. 6, 8-30, 2-4.
4. Hickey A.J. Pharmaceutical inhalation aerosol powder dispersion - an unbalancing act. Am Pharm Rev 2003, 6:106-110.
5. Islam N., Gladki E. Dry powder inhalers (DPIs) - a review of device reliability and innovation. Int J Pharm 2008, 360:1-11.
6. Coates M.S., Chan H.-K., Fletcher David F., Chiou H. Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhaler. Pharm Res 2007, 24:1450-1456.
7. Coates M.S., Chan H.-K., Fletcher David F., Raper Judy A. Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses. Pharm Res 2005, 22:1445-1453.
8. Adi H., Traini D., Chan H.-K., Young P.M. The influence of drug morphology on the aerosolisation efficiency of dry powder inhaler formulations. J Pharm Sci 2008, 97:2780-2788.
9. Dunbar C.A., Hickey A.J., Holzner P. Dispersion and characterization of pharmaceutical dry powder aerosols. Kona 1998, 16:7-45.
10. Clarke M.J., Tobyn M.J., Staniforth J.N. Physicochemical factors governing the performance of nedocromil sodium as a dry powder aerosol. J Pharm Sci 2000, 89:1160-1169.
11. Corrigan D.O., Corrigan O.I., Healy A.M. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers. Int J Pharm 2006, 322:22-30.
12. Coates M.S., Fletcher D.F., Chan H.-K., Raper Judy A. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics Part 1: grid structure and mouthpiece length. J Pharm Sci 2004, 93:2863-2876.
13. Lavorini F., Magnan A., Dubus Jean C., Voshaar T., Corbetta L., Broeders M., et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 2008, 102:593-604.
14. Bowles N, Cahill E, Haeberlin B, Jones C, Mett I, Mitchell JP, et al. Application of quality by design to inhalation products. RDD Europe 2007; Available at , 2007; 1 pp. 61-70. http://wwwrddonlinecom/.
15. FDA. Pharmaceutical CGMPs for the 21st century - a risk-based approach. Available at ; 2004. http://wwwfdagov/cder/gmp/gmo2004/GMP_finalreport2004htm.
16. Golshahi L., Finlay W.H. Recent advances in understanding gas and aerosol transport in the lungs: application to predictions of regional deposition. Adv Transport Phenom 2009, 1:1-30.
17. Telko M.J., Hickey A.J. Dry powder inhaler formulation. Respir Care 2005, 50:1209-1227.
18. Hersey J.A. Ordered mixing: a new concept in powder mixing practice. Powder Technol 1975, 11:41-44.
19. Coates M.S., Chan H., Fletcher D.F., Raper J.A. Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhaler. Pharm Res 2007, 24:1450-1456.
20. Coates M.S., Fletcher D.F., Chan H., Raper J.A. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: grid structure and mouthpiece length. J Pharm Sci 2004, 93:2863-2876.
21. Coates M.S., Chan H., Fletcher D.F., Raper J.A. Influence of air flow on the performance of a dry powder inhaler using computational and experimental analysises. Pharm Res 2005, 22:1445-1453.
22. Coates M.S., Chan H., Fletcher D.F., Raper J.A. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: air Inlet Size. J Pharm Sci 2006, 95:1382-1392.
23. Coates M.S., Fletcher D.F., Chan H., Raper J.A. The role of capsule on the performance of a dry powder inhaler using computational and experimental analyses. Pharm Res 2005, 22:923-932.
24. Finlay W.H., Martin A.R. Modelling of aerosol deposition with interface devices. J Aerosol Med 2007, 20:S19-S28.
25. Frijlink H.W., Boer A.H.D. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 2004, 1:67-86.
26. Smith I.J., Parry-Billings M. The inhalers of the future? A review of dry powder devices on the market today. Pulmon Pharmacol Ther 2003, 16:79-95.
27. Palander A., Mattila T., Karhu M., Muttonen E. In vitro comparison of three salbutamol-containing multidose dry powder inhalers. Clin Drug Invest 2000, 20:25-33.
28. Chrystyn H. Closer to an 'ideal inhaler' with the Easyhaler: an innovative dry powder inhaler. Clin Drug Invest 2006, 26:175-183.
29. Hindle M., Byron P.R. Dose emissions from marketed dry powder inhalers. Int J Pharm 1995, 116:169-177.
30. Barrowcliffe J., McGlynn P., Ratcliffe S., Sewell M., Sheikh S., Walters M. Beclomethasone dipropionate (BDP) Clickhaler; in vitro performance of a steroid novel dry powder inhaler. Proc Drug Deliv 1997, 8:125-128.
31. Adler D., Kritzman A., Genosar A., Slutski A. Dry powder inhaler. Application: WO 2009, Aespironics Ltd, Israel.
32. Wang Z.L., Grgic B., Finlay W.H. A dry powder inhaler with reduced mouth-throat deposition. J Aerosol Med 2006, 19:168-174.
33. Needham M., Fradley G., Cocks A.P. Investigating the efficiency of reverse cyclone technlogy for drug delivery. Respir Deliv Drug 2010, 2:369-372.
34. Zeng X.M., Jones S., O'Leary D., Phelan M., Colledge J. Delivery of formoterol from a novel multi-dose inhaler Airmax. Respir Med 2002, 96:397-403.
35. Clark A.R., Hollingworth A.M. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers - implications for in vitro testing. J Aerosol Med 1993, 6:99-110.
36. Tiddens H.A., Geller D.E., Challoner P., Speirs R.J., Kesser K.C., Overbeek S.E., et al. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. J Aerosol Med 2006, 19:456-465.
37. Srichana T., Martin G.P., Marriott C. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur J Pharm Sci 1998, 7:73-80.
38. Chew N.Y., Chan H.K. In vitro aerosol performance and dose uniformity between the Foradile Aerolizer and the Oxis Turbuhaler. J Aerosol Med 2001, 14:495-501.
39. Munzel U., Marschall K., Fyrnys B., Wedel M. Variability of fine particle dose and lung deposition of budesonide delivered through two multidose dry powder inhalers. Curr Med Res Opin 2005, 21:827-833.
40. de Boer A.H., Gjaltema D., Hagedoorn P., Frijlink H.W. Comparative in vitro performance evaluation of the Novopulmon 200 Novolizer and Budesonid-ratiopharm Jethaler: two novel budesonide dry powder inhalers. Pharmazie 2004, 59:692-699.
41. Brown B.A.S., Rasmussen J.A., Becker D.P., Friend D.R. A piezo-electronic inhaler for local & systemic applications. Drug Deliv Technol 2004, 4:90-93.
42. Crowder T., Hickey A. Powder specific active dispersion for generation of pharmaceutical aerosols. Int J Pharm 2006, 327:65-72.
43. Tobyn M., Staniforth J.N., Morton D., Harmer Q., Newton M.E. Active and intelligent inhaler device development. Int J Pharm 2004, 277:31-37.
44. Virchow J.C., Crompton G.K., Dal Negro R., Pedersen S., Magnan A., Seidenberg J., et al. Importance of inhaler devices in the management of airway disease. Respir Med 2008, 102:10-19.
45. Meakin B.J., Cainey J.M., Woodcock P.M. Simulated 'in-use' and 'mis-use' aspects of the delivery of terbutaline sulfate from Bricanyl Turbohaler dry powder inhalers. Int J Pharm 1995, 119:103-108.
46. Fyrnys B., Stang N., Wolf-Heuss E. Stability and performance characteristics of a budesonide powder for inhalation with a novel dry powder inhaler device. Curr Opin Pulm Med 2001, 7:S7-S11.
47. Newman S.P., Hirst P.H., Pitcairn G.R. Scintigraphic evaluation of lung deposition with a novel inhaler device. Curr Opin Pulm Med 2001, 7(Suppl. 1):S12-S14.
48. Fenton C., Keating G.M., Plosker G.L. Novolizer: a multidose dry powder inhaler. Drugs 2003, 63:2437-2445.
49. Hassan M.S., Lau R. Effect of particle formulation on dry powder inhalation efficiency. Curr Pharm Des 2010, 16:2377-2387.
50. Smutney C.C., Adamo B., Polidoro J.M., Kinsey P.S., Overfield D., Sahi C.R., et al. Dry powder drug delivery system for pulmonary inhalation to treat endocrine diseases. Application: US 2010, Mannkind Corporation, USA, p. 57pp, Cont-in-part of U S No 484,137.
51. Cheow W.S., Hadinoto K. Preparations of dry-powder therapeutic nanoparticle aerosols for inhaled drug delivery. J Aerosol Res 2010, 25:155-165.
52. Shahiwala A., Misra A. Pulmonary absorption of liposomal levonorgestrel. AAPS PharmSciTech 2004, 5.
53. Valle M.J.d.J., Gonzalez Lopez F., Sanchez Navarro A. Pulmonary versus systemic delivery of levofloxacin. Pulmon Pharmacol Ther 2008, 21:298-303.
54. Overhoff K.A., Clayborough R., Crowley M. Review of the TAIFUN multidose dry powder inhaler technology. Drug Dev Ind Pharm 2008, 34:960-965.
55. Wright T., Morgan F.G., Main M.J. Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinson's disease and other central nervous system disorders. Application: GB 2009, Vectura Group PLC, UK, p. 44 pp.
56. Edwards D.A., Hanes J., Caponetti G., Hrkach J., Ben-Jebria A., Eskew M.L., et al. Large porous particles for pulmonary drug delivery. Science 1997, 276:1868-1871.
57. Geller David E., Konstan Michael W., Smith J., Noonberg Sarah B., Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007, 42:307-313.
58. Hickey Anthony J., Lu D., Ashley Elizabeth D., Stout J. Inhaled azithromycin therapy. J Aerosol Med 2006, 19:54-60.
59. Stoessl A.J. Potential therapeutic targets for Parkinson's disease. Expert Opin Ther Targets 2008, 12:425-436.
60. Anon Method of and apparatus for effecting delivery of fine powders. IP Com J 2008, 8(1B):13.
61. Plumley C., Gorman E.M., El-Gendy N., Bybee C.R., Munson E.J., Berkland C. Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy. Int J Pharm 2009, 369:136-143.
62. Rawat A., Majumder Q.H., Ahsan F. Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation. J Control Release 2008, 128:224-232.
63. Cheatham W.W., Leone-Bay A., Grant M., Fog P.B., Diamond D.C. Pulmonary delivery of inhibitors of phosphodiesterase type 5. Application: WO 2006, Mannkind Corporation, USA, p. 23 pp.
64. Farr S.J., Otulana B.A. Pulmonary delivery of opioids as pain therapeutics. Adv Drug Deliv Rev 2006, 58:1076-1088.
65. Fleischer W., Reimer K., Leyendecker P. Opioids for the treatment of the chronic obstructive pulmonary disease. Application: EP 2005, Euro-Celtique S. A., Luxembourg, 24 pp.
66. Kleinstreuer C., Zhang Z., Donohue J.F. Targeted drug-aerosol delivery in the human respiratory system. Ann Rev Biomed Eng 2008, 10:195-220.
67. Ali R., Jain G.K., Iqbal Z., Talegaonkar S., Pandit P., Sule S., et al. Development and clinical trial of nano-atropine sulfate dry powder inhaler as a novel organophosphorous poisoning antidote. Nanomed 2009, 5:55-63.
68. LiCalsi C., Maniaci M.J., Christensen T., Phillips E., Ward G.H., Witham C. A powder formulation of measles vaccine for aerosol delivery. Vaccine 2001, 19:2629-2636.
69. Edwards D.A., Sung J., Pulliam B., Wehrenberg-Klee E., Schwartz E., Dreyfuss P., et al. Pulmonary delivery of malarial vaccine in the form of particulates. Application: WO: 2005, President and Fellows of Harvard College, USA, p. 25 pp.
70. Smith D.J., Bot S., Dellamary L., Bot A. Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus. Vaccine 2003, 21:2805-2812.
71. Brito L., Chen D., Ge Q., Treco D. Dry powder compositions for RNA influenza therapeutics. Application: US 2007, Nastech Pharmaceutical Company Inc., USA, p. 29 pp.
72. Hickey A.J., Concessio N.M., Oort V.M., Platz R.M. Factors influencing the dispersion of dry powders as aerosols. Pharm Technol 1994, (August):58-84.
73. Louey M.D., Razia S., Stewart P.J. Influence of physico-chemical carrier properties on the in vitro aerosol deposition from interactive mixtures. Int J Pharm 2003, 252:87-98.
74. Telko Martin J., Hickey Anthony J. Dry powder inhaler formulation. Respir Care 2005, 50:1209-1227.
75. Young P.M., Cocconi D., Colombo P., Bettini R., Price R., Steele D.F., et al. Characterization of a surface modified dry powder inhalation carrier prepared by particle smoothing. J Pharm Pharmacol 2002, 54:1339-1344.
76. Zeng X.-M., Martin G.P., Marriott C., Pritchard J. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery. J Pharm Sci 2001, 90:1424-1434.
77. Islam N., Stewart P., Larson I., Hartley P. Effect of carrier size on the dispersion of salmeterol xinafoate from interactive mixtures. J Pharm Sci 2004, 93:1030-1038.
78. Zeng X.M., Martin G.P., Marriott C., Pritchard J. The effects of carrier size and morphology on the dispersion of salbutamol sulfate after aerosolization at different flow rates. J Pharm Pharmacol 2000, 52:1211-1221.
79. Zeng X.M., Martin G.P., Tee S.-K., Ghoush A.A., Marriott C. Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulfate from a dry powder formulation. Int J Pharm 1999, 182:133-144.
80. Islam N., Stewart P., Larson I., Hartley P. Surface roughness contribution to the adhesion force distribution of salmeterol xinafoate on lactose carriers by atomic force microscopy. J Pharm Sci 2005, 94:1500-1511.
81. Louey M.D., Mulvaney P., Stewart P.J. Characterization of adhesional properties of lactose carriers using atomic force microscopy. J Pharm Biomed Anal 2001, 25:559-567.
82. Louey M.D., Stewart P.J. Particle interactions involved in aerosol dispersion of ternary interactive mixtures. Pharm Res 2002, 19:1524-1531.
83. Podczeck F., Newton J.M., James M.B. The adhesion force of micronized salmeterol xinafoate particles to pharmaceutically relevant surface materials. J Phys D: Appl Phys 1996, 29:1878-1884.
84. Traini D., Young P.M., Thielmann F., Acharya M. The influence of lactose pseudopolymorphic form on salbutamol sulfate-lactose interactions in dry powder inhaler formulations. Drug Dev Ind Pharm 2008, 34:992-1001.
85. Adi S., Adi H., Tang P., Traini D., Chan H.-k., Young P.M. Micro-particle corrugation, adhesion and inhalation aerosol efficiency. Eur J Pharm Sci 2008, 35:12-18.
86. Chew N.Y.K., Chan H.-K. Use of solid corrugated particles to enhance powder aerosol performance. Pharm Res 2001, 18:1570-1577.
87. Donovan M.J., Smyth H.D.C. Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations. Int J Pharm 2010, 402:1-9.
88. Kawashima Y., Serigano T., Hino T., Yamamoto H., Takeuchi H. Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate. Int J Pharm 1998, 172:179-188.
89. Kawashima Y., Serigano T., Hino T., Yamamoto H., Takeuchi H. Design of inhalation dry powder of pranlukast hydrate to improve dispersibility by the surface modification with light anhydrous silicic acid (AEROSIL 200). Int J Pharm 1998, 173:243-251.
90. Kawashima Y., Serigano T., Hino T., Yamamoto H., Takeuchi H. A new powder design method to improve inhalation efficiency of pranlukast hydrate dry powder aerosols by surface modification with hydroxypropylmethyl cellulose phthalate nanospheres. Pharm Res 1998, 15:1748-1752.
91. Steckel H., Bolzen N. Alternative sugars as potential carriers for dry powder inhalations. Int J Pharm 2004, 270:297-306.
92. Amaro M.I., Tajber L., Corrigan O.I., Healy A.M. Design of experiment to study the effect of spray dryer operating variables on sugar powders intended for inhalation. J Pharm Pharmacol 2010, 62:1413-1414.
93. Minne A., Boireau H., Horta M.J., Vanbever R. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients. Eur J Pharm Biopharm 2008, 70:839-844.
94. Mullins M.E., Michaels L.P., Menon V., Locke B., Ranade M.B. Effect of geometry on particle adhesion. Aerosol Sci Technol 1992, 17:105-118.
95. Crowder T.M., Louey M.D., Sethuraman V.V., Smyth H.D.C., Hickey A.J. An odyssey in inhaler formulation and design. Pharm Technol North Am 2001, 25:99-113.
96. Larhrib H., Martin G.P., Marriott C., Prime D. The influence of carrier and drug morphology on drug delivery from dry powder formulations. Int J Pharm 2003, 257:283-296.
97. Zeng X.M., Martin G.P., Marriott C., Pritchard J. The influence of carrier morphology on drug delivery by dry powder inhalers. Int J Pharm 2000, 200:93-106.
98. Ikegami K., Kawashima Y., Takeuchi H., Yamamoto H., Isshiki N., Momose D-i., et al. Improved inhalation behavior of steroid KSR-592 in vitro with Jethaler? By polymorphic transformation to needle-like crystals (beta-Form). Pharm Res 2002, 19:1439-1445.
99. Chew N.Y.K., Tang P., Chan H.-K., Raper J.A. How much particle surface corrugation is sufficient to improve aerosol performance of powders?. Pharm Res 2005, 22:148-152.
100. Hassan M.S., Lau R. Inhalation performance of pollen-shape carrier in dry powder formulation with different drug mixing ratios: comparison with lactose carrier. Int J Pharm 2010, 386:6-14.
101. Hassan M.S., Lau R. Feasibility study of pollen-shape drug carriers in dry powder inhalation. J Pharm Sci 2010, 99:1309-1321.
102. Kassem N.M., Ho K.K.l., Ganderton D. The effect of air flow and carrier size on the characteristics of an inspirable cloud. J Pharm Pharmacol 1989, 41:14.
103. Braun M.A., Oschmann R., Schmidt P.C. Influence of excipients and storage humidity on the deposition of disodium cromoglycate (DSCG) in the twin impinger. Int J Pharm 1996, 135:53-62.
104. Steckel H., Mueller B.W. In vitro evaluation of dry powder inhalers II: influence of carrier particle size and concentration on in vitro deposition. Int J Pharm 1997, 154:31-37.
105. French D.L., Edwards D.A., Niven R.W. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J Aerosol Sci 1996, 27:769-783.
106. Byron P.R., Jashnani R. Efficiency of aerosolization from dry powder blends of terbutaline sulphate and lactose NF with different particle size distributions. Pharm Res 1990, 7:S81.
107. Hamishehkar H., Emami J., Najafabadi A.R., Gilani K., Minaiyan M., Mahdavi H., et al. Influence of carrier particle size, carrier ratio and addition of fine ternary particles on the dry powder inhalation performance of insulin-loaded PLGA microcapsules. Powder Technol 2010, 201:289-295.
108. Islam N., Stewart P., Larson I., Hartley P. Lactose surface modification by decantation: are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate from lactose-interactive mixtures?. Pharm Res 2004, 21:492-499.
109. Guchardi R., Frei M., John E., Kaerger J.S. Influence of fine lactose and magnesium stearate on low dose dry powder inhaler formulations. Int J Pharm 2008, 348:10-17.
110. Staniforth J.N. Improvements in dry powder inhaler performance: surface passivation effects. Drug Deliv Lungs 1996, VII:86-89.
111. Adi H., Larson I., Stewart P.J. Adhesion and redistribution of salmeterol xinafoate particles in sugar-based mixtures for inhalation. Int J Pharm 2007, 337:229-238.
112. Bhavna, Ahmad F.J., Mittal G., Jain G.K., Malhotra G., Khar R.K., et al. Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions. Eur J Pharm Biopharm 2009, 71:282-291.
113. Kalantarian P., Rouholamini A.N., Haririan I., Vatanara A., Yamini Y., Darabi M., et al. Preparation of 5-fluorouracil nanoparticles by supercritical antisolvents for pulmonary delivery. Int J Nanomed 2010, 5:763-770.
114. Zhang Y., Zhu J., Tang Y., Chen X., Yang Y. The preparation and application of pulmonary surfactant nanoparticles as absorption enhancers in insulin dry powder delivery. Drug Dev Ind Pharm 2009, 35:1059-1065.
115. Huang M., Ma Z., Khor E., Lim L.-Y. Uptake of FITC-Chitosan nanoparticles by A549 cells. Pharm Res 2002, 19:1488-1494.
116. Chono S., Tanino T., Seki T., Morimoto K. Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes. J Drug Target 2006, 14:557-566.
117. Kho K., Hadinoto K. Effects of excipient formulation on the morphology and aqueous re-dispersibility of dry-powder silica nano-aggregates. Colloids Surf A 2010, 359:71-81.
118. Kho K., Hadinoto K. Aqueous re-dispersibility characterization of spray-dried hollow spherical silica nano-aggregates. Powder Technol 2010, 198:354-363.
119. Grenha A., Seijo B., Remunan-Lopez C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci 2005, 25:427-437.
120. Kawashima Y., Takeuchi H., Yamamoto H., Mimura K. Powdered polymeric nanoparticulate system to improve pulmonary delivery of calcitonin with dry powder inhalation. Proc Inter Symp Controlled Release Bioactive Mater 2000, 27th:229-230.
121. Yamamoto H., Kuno Y., Sugimoto S., Takeuchi H., Kawashima Y. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J Control Release 2005, 102:373-381.
122. Tozuka Y., Takeuchi H. Fine particle design and preparations for pulmonary drug delivery. Drug Deliv Syst 2008, 23:467-473.
123. Desai T.R., Li D., Finlay W.H., Wong J.P. Determination of surface free energy of interactive dry powder liposome formulations using capillary penetration technique. Colloids Surf B Biointerfaces 2001, 22:107-113.
124. Lu D., Hickey Anthony J. Liposomal dry powders as aerosols for pulmonary delivery of proteins. AAPS PharmSciTech 2005, 6:E641-E648.
125. Matilainen L., Jaervinen K., Toropainen T., Naesi E., Auriola S., Jaervinen T., et al. In vitro evaluation of the effect of cyclodextrin complexation on pulmonary deposition of a peptide, cyclosporin A. Int J Pharm 2006, 318:41-48.
126. Ungaro F., d'Emmanuele di Villa Bianca R., Giovino C., Miro A., Sorrentino R., Quaglia F., et al. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs. J Control Release 2009, 135:25-34.
127. Sung J.C., Padilla D.J., Garcia-Contreras L., VerBerkmoes J.L., Durbin D., Peloquin C.A., et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res 2009, 26:1847-1855.
128. Edwards D.A., Chen D., Wang J., Ben-Jebria A. Controlled-release inhalation aerosols respiratory drug delivery VI: biological, pharmaceutical, clinical and regulatory issues relating to optimized drug delivery by aerosol. The international symposium 1998, 187-192.
129. Shoyele S.A. Controlling the release of proteins/peptides via the pulmonary route. Methods Mol Biol 2008, 437:141-148.
130. Sievers R.E. Dry powder aerosol vaccine and antibiotics delivery development to reduce risks of deaths in developing countries. Abstract of Papers, 238th ACS National Meeting: PRES-008 2009.
131. Kersten G., Hirschberg H. Needle-free vaccine delivery. Expert Opin Drug Deliv 2007, 4:459-474.
132. Laube Beth L. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 2005, 50:1161-1176.
133. Wee J.L.K., Scheerlinck J.P.Y., Snibson K.J., Edwards S., Pearse M., Quinn C., et al. Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing. Mucosal Immunol 2008, 1:489-496.
134. Sluetter B., Soema P.C., Ding Z., Verheul R., Hennink W., Jiskoot W. Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen. J Control Release 2010, 143:207-214.
135. Sluetter B., Bal S., Keijzer C., Mallants R., Hagenaars N., Que I., et al. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine 2010, 28:6282-6291.
136. Prego C., Paolicelli P., Diaz B., Vicente S., Sanchez A., Gonzalez-Fernandez A., et al. Chitosan-based nanoparticles for improving immunization against hepatitis B infection. Vaccine 2010, 28:2607-2614.
137. Morton D. Dry powder inhaler formulations comprising surface-modified particles with anti-adherent additives. Application: WO: 2006, Vectura Limited, UK, p. 63 pp.
138. Zhou Q.T., Qu L., Larson I., Stewart P.J., Morton D.A.V. Improving aerosolization of drug powders by reducing powder intrinsic cohesion via a mechanical dry coating approach. Int J Pharm 2010, 394:50-59.
139. Shekunov B.Y., Feeley J.C., Chow A.H.L., Tong H.H.Y., York P. Physical properties of supercritically-processed and micronised powders for respiratory drug delivery. Kona 2002, 20:178-187.
140. Shekunov B.Y., Feeley J.C., Chow A.H.L., Tong H.H.Y., York P. Aerosolisation behaviour of micronised and supercritically-processed powders. J Aerosol Sci 2003, 34:553-568.
141. Raula J., Laehde A., Kauppinen E.I. Aerosolization behavior of carrier-free l-leucine coated salbutamol sulphate powders. Int J Pharm 2009, 365:18-25.
142. Newhouse M.T., Hirst P.H., Duddu S.P., Walter Y.H., Tarara T.E., Clark A.R., et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 2003, 124:360-366.
143. Duddu S.P., Sisk S.A., Walter Y.H., Tarara T.E., Trimble K.R., Clark A.R., et al. Improved lung delivery from a passive dry powder inhaler using an engineered pulmosphere?. Powder Pharm Res 2002, 19:689-695.
144. Richardson P.C., Boss A.H. Technosphere insulin technology. Diabetes Technol Ther 2007, 9:S65-S72.
145. Schatz H. Inhaled insulin and the dream of a needle-free insulin application. Exp Clin Endocrinol Diabetes 2004, 112:285-287.
146. Hickey A.J., Concessio N.M. Descriptors of irregular particle morphology and powder properties. Adv Drug Deliv Rev 1997, 26:29-39.
147. Lucas P., Anderson K., Staniforth J.N. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers. Pharm Res 1998, 15:562-569.
148. Pedersen S., Hansen O.R., Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 1990, 65:308-310.
149. Al-Showair Raid A.M., Tarsin Walid Y., Assi Khaled H., Pearson Stanley B., Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help?. Respir Med 2007, 101:2395-2401.
150. Criee C.P., Meyer T., Petro W., Sommerer K., Zeising P. In vitro comparison of two delivery devices for administering formoterol: foradil P and formoterol ratiopharm single-dose capsule inhaler. J Aerosol Med 2006, 19:466-472.
151. Underwood R., Dufour F., Davies G., Pocock A., Gupta S. Using computer modelling to investigate the effect of inhaler design and patient variation in the deposition of particles in the upper airway of paediatric patient. J Aerosol Med Pulmon Drug Deliv 2009, 22(3):294.
152. Charles D.S., Joel D.K., Lea C., Powel K.G. Development of a disposable dry powder delivery device platform. Respir Drug Deliv 2008, 2:405-408.
153. Wieshammer S., Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors?. Respiration 2008, 75:18-25.
154. van der Palen J., Klein J.J., van Herwaarden C.L., Zielhuis G.A., Seydel E.R. Multiple inhalers confuse asthma patients. Eur Respir J 1999, 14:1034-1037.
155. Molimard M., Raherison C., Lignot S., Depont F., Abouelfath A., Moore N. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003, 16:249-254.
156. Self Timothy H., Arnold Lori B., Czosnowski Lauren M., Swanson Joseph M., Swanson H. Inadequate skill of healthcare professionals in using asthma inhalation devices. J Asthma 2007, 44:593-598.
157. Crowe C.T., Troutt T.R., Chung J.N. Numerical models for two-phase turbulent flows. Annu Rev Fluid Mech 1996, 28:11-43.
158. Balachandar S., Eaton J.K. Turbulent dispersed multiphase flow. Annu Rev Fluid Mech 2010, 42:111-133.
159. Farkas A., Balashazy I., Sxocs K. Characterization of regional and local deposition of inhaled aerosol drugs in the respiratory system by computational fluid and particle dynamics methods. J Aerosol Med 2006, 19:329-343.
160. Zhang Y., Chia T.L., Finlay W.H. Experimental measurement and numerical study of particle deposition in highly idealized mouth-throat models. Aerosol Sci Technol 2006, 40:361-372.
161. Ball C.G., Uddin M., Pollard A. High resolution turbulence modelling of airflow in an idealised human extra-thoracic airway. Comp Fluids 2008, 37:943-964.
162. Longest P.W., Hindle M. Quantitative analysis and design of a spray aerosol inhaler Part 1: effects of dilution air inlets and flow paths. J Aerosol Med Pulmon Drug Deliv 2009, 22:271-283.
163. Longest P.W., Hindle M. Evaluation of the respimat soft mist inhaler using a concurrent CFD and in vitro approach. J Aerosol Med Pulmon Drug Deliv 2009, 22:99-112.
164. Wong W., Fletcher D.F., Traini D., Chan H., Crapper J., Young P.M. Particle aerosolisation and break-up in dry powder inhalers 1: evaluation and modelling of venturi effects for agglomerated systems. Pharm Res 2010, 27:1367-1376.
165. Matida E.A., Finlay W.H., Breuer M., Lange C.F. Improving prediction of aerosol deposition in an idealized mouth using large-eddy simulation. J Aerosol Med 2006, 19:290-300.
166. Jin H.H., Fan J.R., Zeng M.J., Cen K.F. Large eddy simulation of inhaled particle deposition within the human upper respiratory tract. Aerosol Sci 2007, 38:257-268.
167. Apte S.V., Mahesh K., Gorokhovski M., Moin P. Stochastic modeling of atomizing spray in a complex swirl injector using large eddy simulation. P Combust Inst 2009, 32:2257-2266.
168. Robinson R.J., Snyder P., Oldham M.J. Comparison of particle tracking algorithms in commercial CFD packages: sedimentation and diffusion. Inhal Toxicol 2007, 19:517-531.
169. Tong Z.B., Yang R.Y., Chu K.W., Yu A.B., Adi S., Chan H.K. Numerical study of the effects of particle size and polydispersity on the agglomerate dispersion in a cyclonic flow. Chem Eng J 2010, 164:432-441.
170. Tong Z.B., Yang R.Y., Yu A.B., Adi S., Chan H.K. Numerical modelling of the breakage of loose agglomerates of fine particles. Powder Technol 2009, 196:213-221.
171. Adi S., Tong Z.B., Kim H.K., Yang R., Yu A. Impact angles as an alternative way to improve aerosolisation of powders for inhalation?. Eur J Pharm Sci 2010, 41:320-327.
172. Voss A., Finlay W.H. Deagglomeration of dry powder pharmaceutical aerosols. Int J Pharm 2002, 248:39-50.
173. Finlay W.H. The mechanics of inhaled pharmaceutical aerosols: an introduction 2001, Academic Press, London.
174. Jones W.P., Lettieri C. Large eddy simulation of spray atomization with stochastic modeling of breakup. Phys Fluids 2010, 22:115106.
175. Wang L., Vigil R.D., Fox R.O. CFD simulation of shear-induced aggregation and breakage in turbulent Taylor-Couette flow. J Colloid Interf Sci 2005, 285:167-178.
176. Behara S.R.B., Kippax P., McIntosh M.P., Morton D., Larson I., Stewart P. Structural influence of cohesive mixtures of salbutamol sulphate and lactose on aerosolisation and de-agglomeration behaviour under dynamic conditions. Eur J Pharm Sci 2011, 42:210-219.
177. Berard V., Lesniewska E., Andres C., Pertuy D., Laroche C., Pourcelot Y. Dry powder inhaler: influence of humidity on topology and adhesion studied by AFM. Int J Pharm 2002, 232:213-224.
178. Harder C., Lesniewska E., Laroche C. Study of ageing of dry powder inhlaer and metered dose inhaler by atomic force micoscopy. Powder Technol 2011, 208:252-259.
179. Hickey A.J., Mansour H.M., Telko M.J., Xu Z., Smythe H.D.C., Mulder T., et al. Physical characterization of component particules included in dry powder inhalers 1. Strategy review and static characteristics. J Pharm Sci 2007, 96:1282-1301.
180. Raula J., Kurkela J.A., Brown D.P., Kauppinen E.I. Study of the dispersion behaviour of l-leucine containing microparticles synthesized with an aerosol flow reactor method. Powder Technol 2007, 177:125-132.
181. Begat P., Morton D.A.V., Staniforth J.N., Price R. The cohesive-adhesive balances in dry powder inhalar formulations 1: direct quantification by atomic force microscopy. Pharm Res 2004, 21:1591-1597.
182. Paajanen M., Katainen J., Raula J., Kauppinen E.I., Lahtinen J. Direct evidence on reduced adhesion of salbutamol sulphate particles due to l-leucine coating. Powder Technol 2009, 192:6-11.
183. Price R., Young P.M., Edge S., Staniforth J.N. The influence of relative humidity on particle interactions in carrier-based dry powder inhaler formulations. Int J Pharm 2002, 246:47-59.
184. Tsukada M., Iriea R., Yonemochi Y., Noda R., Kamiya H., Watanabe W., et al. Adhesion force measurement of a DPI size pharmaceutical particle by colloid probe atomic force microscopy. Powder Technol 2004, 141:262-269.
185. Davies M., Brindley A., Chen X., Marlow M., Doughty S.W., Shrubb I., et al. Characterization of drug particle surface energetics and Young's modulus by atomic force microscopy and inverse gas chromotography. Pharm Res 2005, 22:1158-1166.
186. Grimsey I.M., Feeley J.C., York P. Analysis of surface energy of pharmaceutical powders by inverse gas chromotography. J Pharm Sci 2002, 91:571-583.
187. Changsan M., Kim H.K., Separovic F., Srichana T. Physicochemical characterization and stability of rifampicin liposome dry powder inhaler formulations for inhalers. J Pharm Sci 2009, 98:628-639.
188. Chawla A., Taylor K.M.G., Newton J.M., Johnson M.C.R. Production of spray dried salbutamol sulphate for use in dry powder aerosol fomulation. Int J Pharm 1994, 108:233-240.
189. Shur J., Harris H., Jones M.D., Kaerger J.S., Price R. The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations. Pharm Res 2008, 25:1931-1940.
190. Behara S.R.B., Kippax P., Larson I., Morton D.A.V., Stewart P. Kinetics of emitted mass - a study with three dry powder inhaler devices. Chem Eng Sci 2011, 66:5284-5292.
191. Behara S.R.B., Larson I., Kippax P., Morton D.A.V., Stewart P. An approach to characterising the cohesive behaviour of powders using a flow titration aerosolisation based methodology. Chem Eng Sci 2011, 66:1640-1648.
192. Han R., Papadopoulos G., Greenspan B.J. Flow field measurement inside the mouthpiece of the Spiros inhaler using particle image velocimetry. Aerosol Sci Technol 2002, 36:329-341.
193. Mendes P.J., Sousa J.M.M., Pinto J.F. Prediction of the deposition of dry powder aerosols. AAPS J 2009, 11:186-194.
194. Boer A.H.d., Chan H.K., Price R. A critical review on lactose-based drug formulation and device studies for dry powder inhalation: which are relevant and what interactions to expect?. Adv Drug Deliv Rev 2011, 10.1016/j.addr.2011.04.004.
195. Louey M.D., Mulvaney P., Stewart P.J. Characterisation of adhesional properties of lactose carriers using atomic force microscopy. J Pharm Biomed 2001, 25:559-567.
196. Mukhopadhyay P., Schreiber H.P. Aspects of acid-base interactions use of inverse gas chromatography. Colloids Surf A 1995, 100:47-71.
197. Voelkel A. Inverse gas chromatography in characterization of surface. Chemom Intell Lab Syst 2004, 72:205-207.
198. Zhou Q., Denman J.A., Gengenbach T., Das S., Qu L., Zhang H., et al. Characterization of the surface properties of a model pharmaceutical fine powder modified with a pharmaceutical lubricant to improve flow via a mechanical dry coating approach. J Pharm Sci 2011, 100:3421-3430.
199. Thielmann F., Naderi M., Traini D., Young M. Impact of lactose polymorphism on salbutamol sulphate lactose interactions in DPI formulations. Proc res drug delivery conf Scottsdale, Arizona 2006, 793-795. USA Davis Healthcare International Publishing, Boca Raton, Florida, USA. R. Dalby, P. Byron, J. Peart, J. Suman, S. Farr, P. Young (Eds.).
200. Saleem I., Smyth H., Telko M. Prediction of dry powder inhaler formulation performance from surface energetics and blending dynamics. Drug Dev Ind Pharm 2008, 34:1002-1010.
201. Tanaka T., Eaton J.K. Sub-Kolmogorov resolution partical image velocimetry measurements of particle-laden forced turbulence. J Fluid Mech 2010, 643:177-206.
202. Newman S.P., Busse W.W. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002, 96:293-304.
203. CPMP. Committee for proprietary medicinal products. The European Agency for Evaluation of Medicinal Products; 1998.
204. CDER. Guidance for industry: metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products. Food and Drug Administration (FDA), Rockville, MD; 1998.
205. IPAC-RS. International pharmaceutical aerosol consortium on regulation and science; 2008.
206. Mitchell J., Newman S., Chan H.-K. In vitro and in vivo aspects of cascade impactor tests and inhaler performance: a review. AAPS PharmSciTech 2007, 8:E110.
207. Dunbar C., Mitchell J. Analysis of cascade impactor mass distributions. J Aerosol Med 2005, 18:439-451.
208. Chrystyn H. The Diskus: a review of its position among dry powder inhaler devices. Int J Clin Pract 2007, 61:1022-1036.
209. Hickey A.J., Crowder T.M. Next generation dry powder inhalation delivery systems. Lung Biol Health Dis 2007, 221:445-460.
210. Son Y.-J., McConville J.T. Advancements in dry powder delivery to the lung. Drug Dev Ind Pharm 2008, 34:948-959.
211. Daniher D.I., Zhu J. Dry powder platform for pulmonary drug delivery. Particuology 2008, 6:225-238.
212. Zainudin B.M., Biddiscombe M., Tolfree S.E., Short M., Spiro S.G. Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution. Thorax 1990, 45:469-473.
213. Vidgren M., Paronen P., Vidgren P., Vainio P., Nuutinen J. In vivo evaluation of the new multiple dose powder inhaler and the Rotahaler using the gamma scintigraphy. Acta Pharm Nord 1990, 2:3-10.
214. Richards R., Dickson C.R., Renwick A.G., Lewis R.A., Holgate S.T. Absorption and disposition kinetics of cromolyn sodium and the influence of inhalation technique. J Pharmacol Exp Ther 1987, 241:1028-1032.
215. Neale M.G., Brown K., Hodder R.W., Auty R.M. The pharmacokinetics of sodium cromoglycate in man after intravenous and inhalation administration. Br J Clin Pharmacol 1986, 22:373-382.
216. Melchor R., Biddiscombe M.F., Mak V.H., Short M.D., Spiro S.G. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 1993, 48:506-511.
217. Vidgren M., Arppe J., Vidgren P., Hyvarinen L., Vainio P., Silvasti M., et al. Pulmonary deposition and clinical response of 99mTc-labeled salbutamol delivered from a novel multiple dose powder inhaler. Pharm Res 1994, 11:1320-1324.
218. Pitcairn G., Lunghetti G., Ventura P., Newman S. A comparison of the lung deposition of salbutamol inhaled from a new dry powder inhaler, at two inhaled flow rates. Int J Pharm 1994, 102:11-18.
219. Borgstrom L., Newman S., Weisz A., Moren F. Pulmonary deposition of inhaled terbutaline: comparison of scanning gamma camera and urinary excretion methods. J Pharm Sci 1992, 81:753-755.
220. Borgstrom L., Bengtsson T., Derom E., Pauwels R. Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbuhaler. Int J Pharm 2000, 193:227-230.
221. Borgstrom L., Derom E., Stahl E., Wahlin-Boll E., Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996, 153:1636-1640.
222. Pitcairn G.R., Lim J., Hollingworth A., Newman S.P. Scintigraphic assessment of drug delivery from the Ultrahaler dry powder inhaler. J Aerosol Med 1997, 10:295-306.
223. Thorsson L., Edsbacker S. Lung deposition of budesonide from a pressurized metered-dose inhaler attached to a spacer. Eur Respir J 1998, 12:1340-1345.
224. Wildhaber J.H., Devadason S.G., Wilson J.M., Roller C., Lagana T., Borgstrom L., et al. Lung deposition of budesonide from Turbuhaler in asthmatic children. Eur J Pediatr 1998, 157:1017-1022.
225. Borgstrom L., Bondesson E., Moren F., Trofast E., Newman S.P. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J 1994, 7:69-73.
226. Newman S.P., Pitcairn G.R., Hirst P.H., Bacon R.E., O'Keefe E., Reiners M., et al. Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Eur Respir J 2000, 16:178-183.
227. Chodosh S., Flanders J.S., Kesten S., Serby C.W., Hochrainer D., Witek T.J. Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aerosol Med 2001, 14:309-315.
228. Pitcairn G.R., Lankinen T., Seppala O.P., Newman S.P. Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient's inspiratory effort. J Aerosol Med 2000, 13:97-104.
229. Newman S., Malik S., Hirst R., Pitcairn G., Heide A., Pabst J., et al. Lung deposition of salbutamol in healthy human subjects from the MAGhaler dry powder inhaler. Respir Med 2002, 96:1026-1032.
230. DeLong M., Wright J., Dawson M., Meyer T., Sommerer K., Dunbar C. Dose delivery characteristics of the AIR pulmonary delivery system over a range of inspiratory flow rates. J Aerosol Med 2005, 18:452-459.
231. Newman S.P., Sutton D.J., Segarra R., Lamarca R., de Miquel G. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration 2009, 78:322-328.